蛋白质组学在代谢相关脂肪性肝病精准诊疗中的研究进展与挑战

摘要/Abstract

摘要： 代谢相关脂肪性肝病(MASLD)已成为全球疾病负担最重的慢性肝病之一,其诊疗理念已从单纯的肝病管理,转向以代谢紊乱为核心的多系统疾病的综合管理。当前传统无创指标在解析MASLD分子机制及实现个体化风险分层方面存在局限性。蛋白质组学技术可通过分析疾病特异性标志物,为 MASLD的精准诊疗提供新方案。本文系统梳理MASLD相关蛋白质组学研究进展,重点探讨黏附G蛋白偶联受体G1(ADGRG1)作为兼具肝脏损伤与肝外风险预警的标志物的潜在价值,分析当前蛋白质组学面临的核心挑战,并展望多组学整合在 MASLD 精准医疗中的应用前景。

何新龙, 范建高, 杨蕊旭. 蛋白质组学在代谢相关脂肪性肝病精准诊疗中的研究进展与挑战[J]. 肝脏, 2026, 31(6): 786-789.

/ 推荐

参考文献

[1] Eslam M, Newsome P N, Sarin S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209.
[2] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79(6): 1542-1556.
[3] Lin H, Lee H W, Yip T C, et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease[J]. JAMA, 2024, 331(15): 1287-1297.
[4] Adams L A, Anstee Q M, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J]. Gut, 2017, 66(6): 1138-1153.
[5] Noureddin M, Rinella M, Taub R, et al. Effects of resmetirom on metabolic-dysfunction associated steatohepatitis in patients with weight loss and/or diabetes taking glucagon-like peptide-1 receptor agonists and other diabetes therapies: a secondary analysis of the MAESTRO-NASH trial[J]. Aliment Pharmacol Ther, 2025, 62(11-12): 1089-1099.
[6] Pirola C J, Diambra L, Fernandez Gianotti T, et al. Organ damage proteomic signature identifies patients with MASLD at risk of systemic complications[J]. Hepatology, 2026, 83(3): 623-638.
[7] Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis[J]. Lipids Health Dis, 2024, 23(1): 117.
[8] Loomba R, Friedman S L, Shulman G I. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021, 184(10): 2537-2564.
[9] Miller D M, Mccauley K F, Dunham-Snary K J. Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances[J]. Endocrinol Diabetes Metab, 2025, 8(6): e70132.
[10] Friedman S L, Neuschwander-Tetri B A, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922.
[11] Barbhuiya P A, Yoshitomi R, Pathak M P. Understanding the link between sterol regulatory element binding protein (SREBPs) and metabolic dysfunction associated steatotic liver disease (MASLD)[J]. Curr Obes Rep, 2025, 14(1): 36.
[12] Bo T, Gao L, Yao Z, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease[J]. Cell Metab, 2024, 36(5): 947-968.
[13] An P, Wei L L, Zhao S, et al. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis[J]. Nat Commun, 2020, 11(1): 2362.
[14] Gonzalez A, Huerta-Salgado C, Orozco-Aguilar J, et al. Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD)[J]. Oxid Med Cell Longev, 2020, 2020: 1617805.
[15] Zhuang Y P, Zhang Y T, Zhang R X, et al. The Gut-liver axis in nonalcoholic fatty liver disease: association of intestinal permeability with disease severity and treatment outcomes[J]. Int J Clin Pract, 2022, 2022: 4797453.
[16] Zhang R, Yan Z, Zhong H, et al. Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment[J]. Hepatol Commun, 2024, 8(7).
[17] Gautheron J, Gores G J, Rodrigues C M P. Lytic cell death in metabolic liver disease[J]. J Hepatol, 2020, 73(2): 394-408.
[18] Shojaie L, Iorga A, Dara L. Cell death in liver diseases: a review[J]. Int J Mol Sci, 2020, 21(24).
[19] Pirola C J, Fernandez Gianotti T, Sookoian S. The proteomics of MASLD progression: insights from functional analysis to drive the development of new therapeutic solutions[J]. Aliment Pharmacol Ther, 2025, 61(4): 614-627.
[20] Jia X, Song E, Liu Y, et al. Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese[J]. Cell Rep Med, 2023, 4(11): 101257.
[21] Sakane S, Hikita H, Shirai K, et al. Proteomic analysis of serum extracellular vesicles reveals fibulin-3 as a new marker predicting liver-related events in MASLD[J]. Hepatol Commun, 2024, 8(6).
[22] Pan L, Shen M, Liu Y, et al. Proteomic signature of metabolic dysfunction-associated steatotic liver disease and risk of atherosclerotic cardiovascular disease[J]. Cardiovasc Diabetol, 2025, 25(1): 20.
[23] Zhang J, Wang W, Wang X Q, et al. A robust diagnostic model for high-risk MASH: integrating clinical parameters and circulating biomarkers through a multi-omics approach[J]. Hepatol Int, 2025, 19(4): 820-835.
[24] Ding J, Liu H, Zhang X, et al. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population[J]. Sci Transl Med, 2024, 16(772): eadh9940.